drugset / Trial / NCT00615576

Repeat Dose Study in Male Healthy Volunteer Smokers

NCT00615576

Phase 1 Completed 13 enrolled GlaxoSmithKline
RandomizedSingle-groupTreatment

Summary

This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers

Timeline

Start
2008-03-26
Primary completion
2008-07-24
Completion
2008-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ELUBRIXIN Small molecule 100 mg Oral